Monitoring for PML During Tysabri Treatment: A Guide to Follow-Up Tests

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Vigilance to Specific Drug Safety

If you or a loved one is taking Tysabri, staying on top of routine monitoring is essential for catching potential complications early. The medical community has long recognized that post-market surveillance is critical for ensuring drug safety, especially for therapies with known risks. This page outlines the key follow-up tests and exams recommended for patients on Tysabri to help detect progressive multifocal leukoencephalopathy (PML) as early as possible.

Tysabri and PML: A Documented Causal Association

Tysabri (natalizumab) is a monoclonal antibody indicated for the treatment of multiple sclerosis and Crohn's disease. Its use is associated with a significantly increased risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic viral infection of the brain caused by the JC virus (JCV). The U.S. Food and Drug Administration (FDA) has issued a boxed warning for Tysabri, stating that the drug "increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain that usually leads to death or severe disability" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This warning is prominently displayed in the prescribing information and underscores the gravity of the risk. The clinical presentation of PML is characterized by progressive neurological deficits, including cognitive impairment, motor dysfunction, and visual disturbances. Diagnosis typically involves magnetic resonance imaging (MRI) showing white matter lesions and detection of JCV DNA in cerebrospinal fluid. The FDA label notes that PML "usually leads to death or severe disability" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). In clinical trials, PML occurred in three patients receiving Tysabri: two among 1869 multiple sclerosis patients treated for a median of 120 weeks, and one among 1043 Crohn's disease patients after eight doses (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These cases highlight the real-world occurrence of this devastating adverse event.

Mechanism and Risk Factors for PML with Tysabri

The mechanistic pathway linking Tysabri to PML involves its pharmacological action. Tysabri is an alpha-4 integrin antagonist that inhibits lymphocyte adhesion and migration across the blood-brain barrier, thereby reducing inflammatory activity in the central nervous system. However, this immunosuppressive effect can impair immune surveillance against JCV, a virus that is latent in most individuals. The FDA label identifies three key risk factors for PML: "the presence of anti-JCV antibodies, duration of therapy, and prior use of immunosuppressants" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Anti-JCV antibodies indicate prior exposure to the virus, and their presence increases the risk of PML. Longer treatment duration, especially beyond two years, is associated with higher risk. Prior use of immunosuppressants may further compromise immune function, compounding the risk. The adequacy of warnings regarding Tysabri and PML is a critical consideration. The FDA boxed warning is explicit and requires that "TYSABRI dosing should be withheld immediately at the first sign or symptom suggestive of PML" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Additionally, Tysabri is only available through a restricted distribution program called the TOUCH Prescribing Program, which mandates prescriber and patient education about PML risks (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Despite these measures, the risk remains substantial, and patients must be carefully monitored.

Evidence from Post-Marketing Surveillance and Causation Timeline

The FDA Adverse Event Reporting System (FAERS) data show that Tysabri is associated with a wide range of adverse events, including fatigue, multiple sclerosis relapse, headache, and gait disturbance, but PML is the most serious (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI). The high frequency of neurological symptoms in FAERS reports underscores the need for vigilance. Causation-related considerations for affected patients involve establishing a link between Tysabri exposure and PML. The FDA label states that PML "has occurred in patients who have received TYSABRI" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962), indicating a causal association. The timeline between exposure and documented harm is variable. In clinical trials, PML developed after a median of 120 weeks in multiple sclerosis patients and after eight doses in a Crohn's disease patient (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This suggests that PML can occur after both short-term and long-term use, though risk increases with duration. Patients who develop PML typically experience rapid neurological deterioration, and the condition is often fatal or leads to severe disability. In summary, Tysabri is associated with a well-documented risk of PML, as highlighted by the FDA boxed warning. The pharmacological mechanism involves impaired immune surveillance due to lymphocyte inhibition. Risk factors include anti-JCV antibodies, longer treatment duration, and prior immunosuppressant use. Warnings are robust, but the risk persists, and patients must be monitored closely. The timeline from exposure to PML can range from months to years, and causation is supported by clinical trial data and post-marketing reports.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the FDA warning about Tysabri and PML?

The FDA has issued a boxed warning for Tysabri (natalizumab) stating that it increases the risk of progressive multifocal leukoencephalopathy (PML), a severe brain infection that usually leads to death or severe disability. The warning is prominently displayed in the prescribing information (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

What are the risk factors for developing PML while on Tysabri?

The FDA label identifies three key risk factors: the presence of anti-JCV antibodies, longer duration of therapy (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

How is PML diagnosed in patients taking Tysabri?

Diagnosis typically involves magnetic resonance imaging (MRI) showing white matter lesions and detection of JC virus DNA in cerebrospinal fluid. The FDA label notes that PML usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.